What's Past Is Prologue: Lessons Learned and the Need for Further Development of Allogeneic Hematopoietic Stem Cell Transplantation for Renal Cell Carcinoma

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 1, 2007, Pages 31-33

  Ueno, Naoto T ^a   Childs, Richard W ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SORAFENIB; SUNITINIB; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; OVERALL SURVIVAL; PATIENT CARE; SOLID TUMOR; TREATMENT OUTCOME; TUMOR REGRESSION; WHOLE BODY RADIATION;

EID: 33846001327     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.09.011     Document Type: Note

References (8)

1. Rini B.I., Halabi S., Barrier R., et al. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB Intergroup Phase II Study. Biol Blood Marrow Transplant 12 (2006) 778-785
2. Thomas E.D., and Blume K.G. Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 5 (1999) 341-346
3. Takahashi Y., and Childs R.W. Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma. Clin Cancer Res 10 (2004) 6353S-63539S
4. Ueno N.T., Cheng Y.C., Rondon G., et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102 (2003) 3829-3836
5. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343 (2000) 750-758
6. Bregni M., Dodero A., Peccatori J., et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99 (2002) 4234-4236
7. Rini B.I., Zimmerman T., Stadler W.M., et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 20 (2002) 2017-2024
8. Bregni M., Ueno N.T., and Childs R. The second international meeting on Allogeneic Transplantation in Solid Tumors (ATST). Bone Marrow Transplant 38 8 (2006) 527-537